fbpx

Tempus Time Trials

Sermonix SMC 18-001 (Elaine I)

An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Preand Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation

Sermonix SMX 20-001 (Elaine II)

An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination with Abemaciclib for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and have an ESR1 Mutation

 Elevation Oncology ELVCAP-001-01

A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

 TP Therapeutics TPX-0005-01

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

 Calithera Biosciences CX-839014

A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

AbbVie M16-109 (REFINE)

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Ayala AL-TNBC-01 Tenacity

A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

EMD Insight 2

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC

Janssen NORSE

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Janssen THOR

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

Janssen Amplitude

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Janssen CAN2002/RAGNAR

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

Zentalis ZN-c3-001

A Study of ZN-c3 in Participants With Solid Tumors

LEAP DisTinGuish

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Merus MCLA-128

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Novellus PLX120-03

A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

Fort Wayne North Office
(260) 484-8830
2514 E Dupont Road, Suite 100
Fort Wayne, IN 46825

Fort Wayne South Office
(260) 436-0800
7910 West Jefferson Boulevard, Suite 108
Fort Wayne, Indiana 46804

©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.